Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Vaxess Technologies engages in developing biomedical innovations with a focus on improving access to vaccines.
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Surrozen is a biopharmaceutical that focuses on unlocking the body’s regenerative power to treat injury and disease.
Curevo is a clinical-stage biotechnology company developing next-generation, non-mRNA vaccines for infectious diseases.
Claris Biotherapeutics develops a topical formulation intended to cure corneal wounds, ulcers, and scars.
Genetix Biotherapeutics develops and delivers approved gene therapies for severe rare genetic diseases like sickle cell.
Abcuro develops immunotherapies to treat autoimmunity and cancer.
GH Research is a biopharmaceutical company developing novel therapies for the management of mental illness.
89bio is a biopharmaceutical company that develops clinical-stage therapies for liver and cardiometabolic diseases.
Third Harmonic Bio is a clinical-stage company developing a first-in-class, highly selective, and oral kit inhibitor.
Rivus Pharmaceuticals operates as a biopharmaceutical company dedicated to improving cardio-metabolic health.
Be Biopharma develops engineered B cell medicines for serious genetic diseases.
Inhibrx is a clinical-stage biotechnology company that focuses on developing a broad pipeline of biologic therapeutic candidates.
Verdiva Bio creates cutting-edge treatments that improve results for patients with obesity and cardiometabolic diseases.
Interius BioTherapeutics is a biotechnology company that delivers genetic medicines for patients.
TScan Therapeutics is a biopharmaceutical company focused on the development of immunotherapy treatments for cancer.
New Amsterdam is a clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases.
MARS provides digital financial services with unique card options and rewards programs.
Janux Therapeutics develops immunotherapies that generates immune responses to prevent tumors and not affecting a patient’s healthy tissue.
Bia Energy is transforming LatAm’s power sector with smart meters and a digital platform for real-time control, savings, and sustainability.
ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs.
Cortica provides neurological therapies for children with autism and other developmental differences.
We provide neurodegenerative disease patients with expert MDs and 24/7 wrap around care, no matter where you live in the US
Metsera is a clinical‐stage biotech firm developing oral & injectable hormone therapies to treat obesity & related metabolic diseases.
RA Capital Management has invested in 467 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
RA Capital Management's top investment sectors include Biotechnology, Health Care, Pharmaceutical, Medical, Biopharma. The firm invests across 21 different industry categories.
Among tracked funding rounds, New Amsterdam Pharma received $452.6M in a Post Ipo Equity round. RA Capital Management's total known invested capital is $56.7B.
RA Capital Management's average investment size is $123.5M across its portfolio of 467 companies.
Recent RA Capital Management portfolio additions include Vaxess Technologies, Edgewise Therapeutics, Surrozen, Curevo, Claris Biotherapeutics. These companies were founded in 2020 or later.